Meta-analysis of mir-149 rs2292832 polymorphism.

<p>Random effects model was used when <i>P</i> value of Q-test for heterogeneity test (<i>P_Het</i>)<0.05; otherwise, fixed effect model was used.</p>a<p>Number of studies involved.</p><p>OR: odds ratio; CI: confidence interval.</p

Characteristics of eligible studies in meta-analysis.

<p>HCC: hepatocellular cancer; BC: breast cancer; GBC: gallbladder cancer; GC: gastric cancer; NSCLC: non-small cell lung carcinoma; CC: cervical cancer; LC: lung cancer; EC: esophageal cancer; PC: prostate cancer; HNSCC: head and neck squamous cell carcinoma; NHL: Non-Hodgkin lymphoma; OC: ovarian cancer; PTC: papillary thyroid carcinoma; NSCLC: non-small cell lung cancer; RCC: renal cell carcinoma; UBC: urinary bladder cancer; CRC: colorectal cancer; ESCC: esophageal squamous cell carcinoma; NPC: Nasopharyngeal Carcinoma; OSCC: oral squamous cell carcinoma; HWE: Hardy-Weinberg equilibrium; PCR-RFLP: polymerase chain reaction-restriction fragment length polymorphism; PCR–LDR: polymerase chain reaction–ligation detection reaction; PCR-FRET: polymerase chain reaction–fluorescent resonance energy transfer; HRMA: high-resolution melting analysis; PCR-CTPP: polymerase chain reaction with confronting two-pair primers; Tm-shift: Melting-temperature–shift allele-specific genotyping; HB: hospital based; PB: population based; NR: not reported;</p>*<p>Let7f-2 rs17276588 deviated from HWE in controls.</p>$<p>mir-492 rs2289030 and mir-149 rs2292832 deviated from HWE in controls.</p>#<p>Cirrhosis patients without HCC served as controls.</p>@<p>miR-499 rs3746444 deviated from HWE in controls.</p>!<p>mir196a2 rs11614913 and mir146a rs2910164 deviated from HWE in controls.</p>&<p>miRNA149 rs2292832 deviated from HWE in controls.</p

Meta-analysis of mir-146a rs2910164 polymorphism.

<p>Random effects model was used when <i>P</i> value of Q for heterogeneity test (<i>P_Het</i>)<0.05; otherwise, fixed effect model was used.</p>a<p>Number of studies involved.</p>*<p>The study by Lung et al., <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0050966#pone.0050966-Lung1" target="_blank">[85]</a> has both hospital based and population based controls.</p><p>OR: odds ratio; CI: confidence interval.</p

Meta-analysis of mir-499 rs3746444 polymorphism.

<p>Random effects model was used when <i>P</i> value of Q-test for heterogeneity test (<i>P_Het</i>)<0.05; otherwise, fixed effect model was used.</p>a<p>Number of studies involved.</p><p>OR: odds ratio; CI: confidence interval.</p

Description of meta-analyses included in the systematic review.

<p>BC: breast cancer; GBC: gallbladder cancer; GC: gastric cancer; LC: lung cancer; PC: prostate cancer; HNSCC: head and neck squamous cell carcinoma; PTC: papillary thyroid carcinoma; ESCC: esophageal squamous cell carcinoma; HCC: hepatocellular cancer; CRC: colorectal cancer; OSCC: oral squamous cell carcinoma; PSCC: pharynx squamous cancer; OC: ovarian cancer; CC: cervical cancer; RCC: renal cell cancer.</p>*<p>Considered T allele as variant allele as in the present study.</p><p>P_het, <i>p</i>-value for heterogeneity.</p><p>OR, odds ratio.</p><p>CI, confidence interval.</p>*<p>Homozygous wild vs. homozygous variant genotype.</p

Clinical-pathological characteristics of the prostate cancer patients.

<p>Clinical-pathological characteristics of the prostate cancer patients.</p

Comparison of miRNA expression on the basis of ethnicity.

<p>Box plots represent the fold difference in expression levels of four miRNAs in PCa tissues as compared to their normal adjacent counterpart. Data for 15 Caucasian American (CA) and 25 African American (AA) patients as assessed by qRT-PCR is shown. Expression levels of the miRNAs were normalized to U6 snRNA as endogenous control. Statistically significant differences were determined using unpaired Student’s T-test.</p

Demographic and clinico-pathological characteristics of the participants for urine samples.

<p>Demographic and clinico-pathological characteristics of the participants for urine samples.</p

Pathway network of the genes targeted by differentially modulated miRNAs.

<p>Pathway network was constructed for commonly predicted target mRNAs of differentially modulated miRNAs (miR-205, miR-214, miR-221 and miR99b), by using Pathway Studio 9.0 (A) Commonly predicted miRNA targets with common regulators. (B) Directly interacting targets.</p

Differentially expressed miRNAs in Prostate Cancer Tissues.

*<p>miRNAs selected for tissue validation.</p